Objectives: To evaluate in vitro interactions between paromomycin sulphate and the antileishmanial drugs meglumine antimoniate, amphotericin B, miltefosine and azithromycin against intracellular Leishmania (Leishmania) infantum chagasi, Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis amastigotes in peritoneal mouse macrophages.
Introduction
The current options to treat cutaneous and visceral forms of leishmaniasis include pentavalent antimonials, amphotericin B (as deoxycholate or liposomal formulations), miltefosine and the aminoglycoside paromomycin. 1 Although this therapeutic arsenal is more promising than that which was available many decades ago, it is far from satisfactory due to its many disadvantages. Resistance to pentavalent antimonials, which have been the first-line drugs to treat cutaneous and visceral leishmaniasis, is now widespread in the Indian subcontinent. 2 New drug formulations such as amphotericin B, and its lipid formulations, and miltefosine have shown efficacy in treating leishmaniasis, but their high cost, parenteral administration, long term-therapy and potentially severe side effects limit the use of these drugs. 3, 4 In this context, drug combinations are strategic alternatives for antileishmanial treatment. Possible favourable outcomes of multidrug therapy include drug synergism and increased efficacies, reduced dosages and treatment durations with subsequent decreases in toxicities and costs and delays or prevention of drug resistance. Treatment schedules with drug combinations have been tested mainly against Old World visceral leishmaniasis, both in experimental models and in humans.
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Here we report on the in vitro interactions between paromomycin and four other drugs with leishmanicidal activity against three Leishmania species of medical relevance in the Americas. This study aimed to construct a database for a rational approach to the identification of useful paromomycin combinations in the treatment of New World cutaneous and visceral leishmaniasis. The determination of IC 50 and IC 90 values of individual drugs was performed using the amastigote-macrophage assay. 12 Incubation time and concentration ranges of azithromycin, meglumine antimoniate and miltefosine evaluated for each species of Leishmania were defined from previous studies. 12 -14 Incubation time and the concentration ranges for amphotericin B and paromomycin were determined in preparation for this assay. The plates were incubated with drugs for 3, 5 and 7 days at 378C in 5% CO 2 . Further medium changes with fresh drugs were performed after 3 days in the 5 day assays and after 3 and 5 days in the 7 day assays. The assay results were analysed if at least 80% of the macrophages in the control wells were infected (assay quality control).
The results were obtained as ratios of the proportion of infection (amastigotes/100 macrophages) between the treated and non-treated cultures and were expressed as IC 50 and IC 90 as calculated by linear regression analysis (MiniTab 13.0) or linear interpolation (Microsoft Office Excel 2003) according to Huber and Koella. 15 
In vitro drug interaction assays
The interactions between the drugs were assessed using a modified fixed-ratio isobologram method according to Fivelman et al. 16 Predetermined IC 50 values were used to decide the maximum concentrations of the individual drugs after ensuring that the IC 50 values fell near the midpoint of a six-point 2-fold dilution series. The optimal time of action of the drugs in combination was chosen to establish a common time for the use of the two related drugs without prejudice to the actions of either.
The fractional inhibitory concentrations (FICs) and the sum FICs ( FICs) were calculated as follows: FIC of paromomycin sulphate¼IC 50 
Results

In vitro susceptibility of intracellular amastigotes to individual drugs
The individual IC 50 and IC 90 values that were calculated for different periods of drug exposure are given in Table 1 as mM and mg/mL concentrations. All Leishmania isolates were susceptible to the drugs. No toxicity towards macrophages was observed at the drug concentrations used in this study, based on morphological observations.
In vitro drug interactions against intracellular amastigotes in peritoneal macrophages
Interactions between paromomycin sulphate and other drugs were assessed with a modified fixed-ratio method, and the data were analysed at IC 50 and IC 90 levels. Table 2 observed in the assessments of drug associations for Leishmania donovani and Plasmodium falciparum, in which the interactions were classified from indifferent at the IC 50 level to synergistic at the IC 90 level, and from indifferent at the IC 50 level to synergistic at the IC 90 and IC 99 levels, respectively.
6,18
These in vitro experimental data indicate synergistic associations between currently used antileishmanial drugs and paromomycin sulphate against the three tested Leishmania species. At least two associations were synergistic against the three species evaluated: against L. (L.) amazonensis, paromomycin plus amphotericin B and paromomycin plus miltefosine; against L. (V.) braziliensis, paromomycin plus meglumine antimoniate and paromomycin plus amphotericin B; and against L. (L.) infantum chagasi, paromomycin plus meglumine antimoniate, paromomycin plus amphotericin B and paromomycin plus azithromycin.
Drug interactions were previously studied for Leishmania (Leishmania) donovani. Seifert and Croft 6 observed a synergistic interaction between miltefosine and sodium stibogluconate and indifference when miltefosine was combined with amphotericin B, paromomycin or sitamaquine. In another study, the interaction between miltefosine and amphotericin B was also considered to be indifferent.
6, 19 Seifert et al. 20 evaluated the interactions between sitamaquine and five other antileishmanial drugs and found synergism between sitamaquine and pentamidine.
Although our in vitro study has provided evidence for synergistic and indifferent (additive) antileishmanial combinations, these data do not necessarily imply in vivo effectiveness and indifference, respectively. Seifert and Croft, 6 for example, did not observe in vitro synergism for the combinations of miltefosine and paromomycin or miltefosine and amphotericin B against L. (L.) donovani, but in vivo tests indicated enhanced activity of these same combinations. Thus, in vivo tests of antileishmanial drugs in combination against these three Leishmania species are currently ongoing.
This work provides an in vitro preclinical dataset that supports future studies addressing multidrug treatment schedules against New World leishmaniasis. 
